Cargando…
Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
Diabetic retinopathy (DR) is a complication of diabetes and one of the leading causes of vision loss worldwide. Despite extensive efforts to reduce visual impairment, the prevalence of DR is still increasing. The initial pathophysiology of DR includes damage to vascular endothelial cells and loss of...
Autores principales: | Tomita, Yohei, Lee, Deokho, Tsubota, Kazuo, Negishi, Kazuno, Kurihara, Toshihide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537579/ https://www.ncbi.nlm.nih.gov/pubmed/34682788 http://dx.doi.org/10.3390/jcm10204666 |
Ejemplares similares
-
PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020) -
PPARα Modulation-Based Therapy in Central Nervous System Diseases
por: Lee, Deokho, et al.
Publicado: (2021) -
Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?
por: Lee, Deokho, et al.
Publicado: (2022) -
Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion
por: Lee, Deokho, et al.
Publicado: (2021) -
Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)